Posted by Michael Wonder on 18 May 2021
Essilor receives FDA breakthrough device designation for Essilor Stellest, its new generation of spectacle lens solutions in the fight against myopia
17 May 2021 - Essilor today announced that the U.S. FDA has granted breakthrough device designation to its Essilor Stellest spectacle lens, the Company’s new generation lens developed to correct myopia and slow down the progression of myopia in children.
After the first year, the trial results demonstrated that the eye growth of 9 out of 10 children wearing the Essilor Stellest lens was similar or slower than non-myopic children. While after two years, Essilor Stellest lens has been proven to be among the most effective myopia control solutions which have ever been tested.
